NIRAPK : Study of the Relationship(s) Between Clinical, Biological and Pharmacokinetic Metrics and Toxicities When Niraparib is Used as Maintenance Treatment for Ovarian Cancer Patients.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hospices Civils de Lyon
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Patient Study Information and written informed consent
Social Security Affiliation
Patient \> 18 years old.
Ovarian, tubular or peritoneal high-grade epithelial carcinoma, histologically proven. Recommendation of a maintenance treatment with Niraparib at standard dose (200-300mg/day)
Glomerular filtration rate with standardized serum creatinine values using CKD-EPI formula ≥ 30ml/min/1.73m2 (https://www.kidney.org/professionals/kdoqi/gfr\_calculator)
Normal liver function with bilirubin \< 1.5N
6-8 weeks break between last chemotherapy and Niraparib treatment initiation.
Patient with an effective birth control
You may not be if
Minor patient
Patient not able to understand the aim of the study or under curatorship
Low grade carcinoma
Pregnant or breastfeeding patient
Hypersensivity to an active substance present in niraparib
Clareo Health | NIRAPK : Study of the Relationship(s) Between Clinical, Biological and Pharmacokinetic Metrics and Toxicities When Niraparib is Used as Maintenance Treatment for Ovarian Cancer Patients.
